Lakefront Biotherapeutics
Other OTCTotal Valuation
Lakefront Biotherapeutics carries a market capitalization of 2.11B, placing it among publicly traded companies globally. Its enterprise value stands at -619.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.11B |
| Enterprise Value | -619.49M |
Share Statistics
Lakefront Biotherapeutics currently has 65.66M shares outstanding.
| Shares Outstanding | 65.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Lakefront Biotherapeutics trades at a trailing price-to-earnings ratio of 2.71. The price-to-sales ratio is 1.63, and the price-to-book ratio stands at 0.49.
| PE Ratio | 2.71 |
| PS Ratio | 1.63 |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | -7.28 |
| P/OCF Ratio | -7.14 |
Financial Position
Lakefront Biotherapeutics maintains a current ratio of 32.84, meaning it holds 32.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 32.84 |
| Quick Ratio | 32.65 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | 20.20 |
| Return on Assets (ROA) | 16.64 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 46.82 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.19 |
Taxes
Over the trailing twelve months, Lakefront Biotherapeutics has paid -16.69M in income taxes, reflecting an effective tax rate of 4.06.
| Income Tax | -16.69M |
| Effective Tax Rate | 4.06 |
Stock Price Statistics
Lakefront Biotherapeutics's stock has declined approximately -4.4843% over the past 52 weeks. The 50-day moving average sits at 27.41, while the 200-day moving average is 29.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | -4.4843% |
| 50-Day Moving Average | 27.41 |
| 200-Day Moving Average | 29.94 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lakefront Biotherapeutics generated 990.57M in revenue and converted that into 596.64M in net income, yielding earnings per share of 9.02. EBITDA reached 609.91M, while operating income came in at 609.91M.
| Revenue | 990.57M |
| Gross Profit | 965.33M |
| Operating Income | 609.91M |
| Pretax Income | 577.63M |
| Net Income | 596.64M |
| EBITDA | 609.91M |
| EBIT | 609.91M |
| Earnings Per Share (EPS) | 9.02 |
Balance Sheet
Lakefront Biotherapeutics holds 2.24B in cash and equivalents against 6.36M in total debt, resulting in a net debt position of -135.95M. Total book value stands at 3.26B, with working capital of 2.24B providing operational flexibility.
| Cash & Cash Equivalents | 2.24B |
| Total Debt | 6.36M |
| Net Debt | -135.95M |
| Equity (Book Value) | 3.26B |
| Book Value Per Share | 49.71 |
| Working Capital | 2.24B |
Cash Flow
Lakefront Biotherapeutics produced -226.91M in operating cash flow over the past twelve months. After subtracting -4.61M in capital expenditures, free cash flow totaled -231.51M - equivalent to -3.51 per share.
| Operating Cash Flow | -226.91M |
| Capital Expenditures | -4.61M |
| Free Cash Flow | -231.51M |
| FCF Per Share | -3.51 |
Margins
Lakefront Biotherapeutics operates with a gross margin of 97.45, reflecting its pricing power and cost economics. The operating margin of 61.57 and net profit margin of 60.23 provide insight into operational efficiency.
| Gross Margin | 97.45 |
| Operating Margin | 61.57 |
| Pretax Margin | 58.31 |
| Profit Margin | 60.23 |
| EBITDA Margin | 61.57 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.38 |
| FCF Yield | -13.73 |
Scores
Lakefront Biotherapeutics posts an Altman Z-Score of 13.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.37 |